摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-甲基-7,8-二氢喹啉-2,5(1H,6H)-二酮 | 29707-35-5

中文名称
4-甲基-7,8-二氢喹啉-2,5(1H,6H)-二酮
中文别名
——
英文名称
4-Methyl-5,6,7,8-tetrahydro-5-oxo-2-hydroxyquinoline
英文别名
4-methyl-7,8-dihydroquinoline-2,5( 1H,6H)-dione;2-Hydroxy-5-oxo-4-methyl-5,6,7,8-tetrahydrochinolin;4-methyl-7,8-dihydro-1H,6H-quinoline-2,5-dione;4-methyl-7,8-dihydro-2,5(1H,6H)-quinolinedione;2-Hydroxy-4-methyl-7,8-dihydroquinolin-5(6H)-one;4-methyl-1,6,7,8-tetrahydroquinoline-2,5-dione
4-甲基-7,8-二氢喹啉-2,5(1H,6H)-二酮化学式
CAS
29707-35-5
化学式
C10H11NO2
mdl
——
分子量
177.203
InChiKey
XPZFYNGHMRAKQO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    46.2
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-甲基-7,8-二氢喹啉-2,5(1H,6H)-二酮盐酸羟胺sodium acetate 作用下, 以 乙醇 为溶剂, 反应 3.0h, 以93%的产率得到4-Methyl-5,6,7,8-tetrahydro-5-hydroxyimino-2-hydroxyquinoline
    参考文献:
    名称:
    New perspectives on the Semmler-Wolff aromatization reaction
    摘要:
    DOI:
    10.1021/jo01301a008
  • 作为产物:
    描述:
    5,6,7,8-tetrahydro-2,5-dioxoquinoline-4-acetic acid 以99%的产率得到4-甲基-7,8-二氢喹啉-2,5(1H,6H)-二酮
    参考文献:
    名称:
    New perspectives on the Semmler-Wolff aromatization reaction
    摘要:
    DOI:
    10.1021/jo01301a008
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS<br/>[FR] COMPOSÉS TÉTRAHYDROQUINOLINONE SUBSTITUÉS EN TANT QUE MODULATEURS DE ROR GAMMA
    申请人:AURIGENE DISCOVERY TECH LTD
    公开号:WO2016185342A1
    公开(公告)日:2016-11-24
    The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as RORγ modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
    本发明提供了公式(I)的取代四氢喹啉酮及相关化合物,作为视黄酸受体相关孤儿受体(RORs)的调节剂,在RORγ调节剂方面具有治疗上的用途。这些化合物在治疗和预防疾病和/或紊乱方面具有用途,特别是它们在由RORγ受体介导的疾病和/或紊乱中的用途。本发明还提供了这些化合物的制备以及包含至少一种取代四氢喹啉酮或相关化合物的制剂和药物配方,以及其所用的药学上可接受的载体、稀释剂或赋形剂。
  • Pharmaceutical compositions containing quinolin-2,5-diones, new
    申请人:Karl Thomae GmbH
    公开号:US05068334A1
    公开(公告)日:1991-11-26
    This invention relates to pharmaceutical compositions containing quinolin-2,5-diones of formula ##STR1## wherein A, B, R.sup.1 to R.sup.3 and X are defined hereinbelow, some of which are novel, which compounds have valuable pharmacological properties, particularly analgesic antipyretic and/or antiphlogistic effects, to new intermediates and processes for preparing them.
    这项发明涉及含有式##STR1##的喹啉-2,5-二酮的药物组合物,其中下文定义了A、B、R^1至R^3和X,其中一些是新颖的,这些化合物具有有价值的药理特性,特别是镇痛、退热和/或抗炎作用,以及用于制备它们的新中间体和工艺。
  • Verwendung von Chinolin-2,5-dionen in einem Arzneimittel mit einer analgetischen, antipyretischen und/oder einer antiphlogistischen Wirkung
    申请人:Dr. Karl Thomae GmbH
    公开号:EP0338228A2
    公开(公告)日:1989-10-25
    Die vorliegende Erfindung betrifft Arzneimittel, enthaltend Chinolin-2,5-dione der Formel in der A, B, R₁ bis R₃ und X wie in den Ansprüchen 1 bis 6 definiert sind, sowie neue Chinolin-2,5-dione gemäß den An­sprüchen 10 bis 14, welche wertvolle pharmakologische Eigen­schaften aufweisen, insbesondere eine analgetische, antipyre­tische und/oder antiphlogistische Wirkung, neue Zwischenpro­dukte und Verfahren zu ihrer Herstellung.
    本发明涉及含有 2,5-喹啉二酮的药物,其式为 其中 A、B、R₁至 R₃和 X 如权利要求 1 至 6 所定义,以及根据权利要求 10 至 14 所述的新型喹啉-2,5-二酮,它们具有重要的药理特性,特别是镇痛、解热和/或抗血栓作用,以及制备它们的新型中间体和工艺。
  • METHOD FOR THE PREPARATION OF TETRAHYDROQUINOLINONE COMPOUNDS HAVING ROR-GAMMA MODULATING ACTIVITY
    申请人:Aurigene Discovery Technologies Limited
    公开号:EP3845526A1
    公开(公告)日:2021-07-07
    The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as RORy modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
    本发明提供了取代的四氢喹啉酮和相关的式(I)化合物,它们作为视黄酸受体相关孤儿受体(RORs)的调节剂,特别是作为RORy调节剂,具有治疗作用。这些化合物可用于治疗和预防疾病和/或失调,特别是用于 RORγ 受体介导的疾病和/或失调。本发明还提供了包含至少一种取代的四氢喹啉酮或式(I)相关化合物的化合物和药物制剂的制备方法,以及药学上可接受的载体、稀释剂或赋形剂。
  • Substituted tetrahydroquinolinone compounds as ROR gamma modulators
    申请人:Aurigene Discovery Technologies Limited
    公开号:US11229636B2
    公开(公告)日:2022-01-25
    The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as RORγ modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
    本发明提供了取代的四氢喹啉酮和相关的式(I)化合物,它们作为视黄酸受体相关孤儿受体(RORs)的调节剂,特别是作为RORγ调节剂,具有治疗作用。这些化合物可用于治疗和预防疾病和/或紊乱,特别是用于治疗由 RORγ 受体介导的疾病和/或紊乱。本发明还提供了包含至少一种取代的四氢喹啉酮或式(I)相关化合物的化合物和药物制剂的制备方法,以及药学上可接受的载体、稀释剂或赋形剂。
查看更多